[131I]- and [125I]metaiodobenzylguanidine therapy in macroscopic and microscopic tumors:A comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts

Rutgers, Marja; Buitenhuis, Corine K.M.; Valk, Martin A. van der; Hoefnagel, C.A.; Pa, Voûte; Smets, L. A.

doi:10.1002/1097-0215(20001220)90:6<312::aid-ijc2>3.0.co;2-z

Cited by 17 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the microscopic tumor model, 125 I-MIBG had no antitumor effect. While 131 I-MIBG showed some decrease in tumor growth in this microscopic disease model, the effect was much less pronounced compared with external beam total body irradiation [42]. These results support the current use of 131 I as the radioisotope of choice for MIBG therapy in neuroblastoma, although combination approaches may also be of future interest.…”

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomasupporting

confidence: 61%

“…Xenograft growth was attenuated compared to control-treated mice for up to 12 days following 131 I-MIBG treatment. 131 I-MIBG administered to produce a tumor absorbed dose of 5 Gy was as effective as 5 Gy external beam radiation in reducing tumor growth [42]. This finding is significant since the dose rate following 131 I-MIBG therapy is much lower than the dose rate from external beam radiation.…”

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomamentioning

confidence: 99%

“…This finding is significant since the dose rate following 131 I-MIBG therapy is much lower than the dose rate from external beam radiation. Moreover, fractionated administration of 131 I-MIBG does not appear to improve the efficacy of this therapy compared to the same total dose given as a single treatment [42]. In fact, at least one experiment has suggested that multiple treatments with radiolabeled MIBG may be less effective compared with a single treatment.…”

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomamentioning

confidence: 99%

“…This experiment demonstrated that a second treatment with radiolabeled MIBG to neuroblastoma cells in vitro resulted in reduced cytotoxicity compared to the first treatment using the same dose [35]. The mechanism for this diminished efficacy is unclear, particularly since in vivo experiments have demonstrated that radiolabeled MIBG storage by neuroblastoma xenografts does not differ between initial and subsequent treatments [42]. …”

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomamentioning

confidence: 99%

“…125 I-MIBG was ineffective in treating 400 micron spheroids, while 131 I-MIBG performed well in treating these larger spheroids [36,44]. 125 I-MIBG has also been compared to 131 I-MIBG in neuroblastoma xenograft models of both macroscopic and microscopic tumors [42]. In the macroscopic tumor model, 125 I-MIBG was considerably less effective at slowing tumor growth compared to 131 I-MIBG.…”

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomamentioning

confidence: 99%

See 4 more Smart Citations

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

DuBois

Matthay

2008

Nuclear Medicine and Biology

View full text Add to dashboard Cite

Introduction Neuroblastoma is the most common pediatric extracranial solid cancer. This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases, prompting the use of radiolabeled MIBG for targeted radiotherapy in these tumors. Methods The available English language literature was reviewed for original research investigating in vitro, in vivo, and clinical applications of radiolabeled MIBG for neuroblastoma. Results MIBG is actively transported into neuroblastoma cells by the norepinephrine transporter. Preclinical studies demonstrate substantial activity of radiolabeled MIBG in neuroblastoma models, with 131I-MIBG showing enhanced activity in larger tumors compared to 125I-MIBG. Clinical studies of 131I-MIBG in patients with relapsed or refractory neuroblastoma have identified myelosuppression as the main dose-limiting toxicity, necessitating stem cell reinfusion at higher doses. Most studies report a response rate of 30–40% with 131I-MIBG in this population. More recent studies have focused on the use of 131I-MIBG in combination with chemotherapy or myeloablative regimens. Conclusions 131I-MIBG is an active agent for the treatment of patients with neuroblastoma. Future studies will need to define the optimal role of this targeted radiopharmaceutical in the therapy of this disease.

show abstract

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomasupporting

confidence: 61%

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomamentioning

confidence: 99%

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomamentioning

confidence: 99%

Section: Preclinical Studies Of Radiolabeled Mibg In Neuroblastomamentioning

confidence: 99%